Results 221 to 230 of about 402,235 (309)

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

Effect of ondansetron in attenuation of post-spinal hypotension in caesarean section: A comparison of two different doses with placebo

, 2017
MeenotiP Potdar, LaxmiL Kamat, TanyaR Jha, AditiS Talnikar, ZakeraM Mahevi, ManjeetP Save   +5 more
openalex   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

[Placebo effect in the treatment with antidepressants : Implications for the scientific evaluation and clinical use of pharmaceutical treatments of depression]. [PDF]

Nervenarzt
Rief W, Kube T.
europepmc   +1 more source

The sedative and propofol-sparing effect of dexmedetomidine and midazolam as premedicants in minor gynecological day care surgeries: A randomized placebo-controlled study

, 2018
Jyoti Vidhan, Anita Kumari, ArvinderPal Singh, Ruchi Gupta, Jonny Dhawan, Jasleen Kaur   +5 more
openalex   +1 more source

N‐of‐1 trials in clinical research: Methodological foundations, statistical approaches and implementation challenges

British Journal of Clinical Pharmacology, EarlyView.
N‐of‐1 trials offer a unique and rigorous methodology for evaluating individualized treatment responses, particularly within the context of personalized medicine. This article provides a comprehensive explanation of the conceptual and methodological underpinnings of N‐of‐1 trials, with particular emphasis on statistical techniques and considerations ...
Marcos Clint Leal De Carvalho, Matheus de Matos Dourado Simões, Ubiratan Cardinalli Adler, Antonio Brazil Viana Junior, Caren Nádia Soares de Sousa, Lia Lira Olivier Sanders   +5 more
wiley   +1 more source

DRY NEEDLING V/S SHAM ACUPUNCTURE [PLACEBO EFFECT] ALONG WITH CONVENTIONAL PHYSIOTHERAPY IN POST-STROKE SURVIVORS WITH SPASTICITY IN THE UPPER EXTREMITY – A COMPARATIVE STUDY

Diya Mody, Ketaki Patani, Shaily Parekh
openalex   +2 more sources

AI ‐ NLME : A New Artificial Intelligence‐Driven Nonlinear Mixed Effect Modeling Approach for Analyzing Longitudinal Data in Randomized Placebo‐Controlled Clinical Trials [PDF]

Roberto Goméni, Françoise Bressolle‐Gomeni   +1 more
openalex   +1 more source

An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paroxetine is a selective serotonin reuptake inhibitor (SSRI), approved for treatment of major depressive disorder and anxiety disorders. Some SSRIs are known to prolong the QT interval; however, clinical evidence to establish a lack of association between paroxetine and corrected QT interval (QTc) prolongation is limited. Therefore, this
Sven C. van Dijkman, Mathieu Félices, Bhaskar Pandurangavittal, Sanman Ghorpade, Caroline Easterbrook, Marcin Zabielski, Oscar Della Pasqua   +6 more
wiley   +1 more source